Innovative Diagnostic Portfolio ALPCO Diagnostics offers a broad portfolio of molecular and immunodiagnostic products focused on infectious and gastroenterological diseases, presenting multiple opportunities to expand sales with research and clinical laboratories seeking high-quality, reliable solutions.

Recent Product Launch The company recently launched the FDA 510(k) cleared Calprotectin Immunoturbidimetric Assay and expanded its GI diagnostic solutions globally, indicating a growing product line that can be promoted to laboratories looking for advanced and validated diagnostic tools.

Strategic Partnerships Partnerships with Dynex Technologies, GeneProof, and Gold Standard Diagnostics enhance ALPCO's automation and multiplex testing capabilities, providing sales channels to introduce integrated diagnostic systems to laboratories interested in automation and comprehensive testing.

Global Expansion Focus ALPCO’s European commercial launch of its new assays illustrates its commitment to international growth, offering opportunities to target European clinical and research labs with tailored outreach and localized solutions.

Leadership & Growth The appointment of a new CEO and consistent product innovation demonstrate a company in growth mode, presenting prospects for proactive engagement with decision-makers interested in innovative diagnostics and scalable lab solutions.